# A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR

> **NCT02178397** · PHASE3 · TERMINATED · sponsor: **Centre Francois Baclesse** · enrollment: 6 (actual)

## Conditions studied

- NSCLC Patients With EGFR Activating Mutation

## Interventions

- **DRUG:** ERLOTINIB WITH CHEMOTHERAPY
- **DRUG:** CHEMOTHERAPY ONLY

## Key facts

- **NCT ID:** NCT02178397
- **Lead sponsor:** Centre Francois Baclesse
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** lack of recruitment
- **Last updated:** 2017-07-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02178397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02178397, "A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02178397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*